Elevance Health, Inc. ELV
429.65 USD +11.40 (+2.73%)
At closeNov 10, 2026, 5:31 PM EST
429.65 0.00 0.00%
After hours · Nov 10, 5:31 PM ET
418.03 Day range 429.79
280.74 52-week range 445.28
- YTD
- +22.56%
- 1 year
- +41.43%
News
247wallst.com CVS Tumbles 12% on Plan to Split Into Two Companies Despite Earnings Beat; Elevance Health Rises 4%, Cigna Climbs 3% Wall Street is punishing CVS Health (NYSE:CVS | CVS Price Prediction) for a plan to break up the pharmacy, benefits and insurance empire it spent years building, even after a strong quarter. CVS…
zacks.com Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know Does Elevance Health (ELV) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492 Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $473 to $492.
gurufocus.com ELV Fairly Valued by DCF at $418 On October 27, 2026, we delve into the DCF analysis for Elevance Health Inc (ELV), a company that has shown notable price performance over the past year, with a
defenseworld.net Elevance Health, Inc. $ELV Stock Acquired by Citizens Financial Group Inc. RI Citizens Financial Group Inc. RI increased its position in shares of Elevance Health, Inc. (NYSE: ELV) by 77.0% in the undefined quarter, according to the company in its most recent 13F filing with…
zacks.com Implied Volatility Surging for Elevance Health Stock Options Investors need to pay close attention to ELV stock based on the movements in the options market lately.
defenseworld.net Elevance Health, Inc. $ELV Stock Sold by Iridian Asset Management LLC CT Iridian Asset Management LLC CT decreased its holdings in Elevance Health, Inc. (NYSE: ELV) by 31.6% in the third quarter, according to its most recent Form 13F filing with the Securities and…
defenseworld.net Elevance Health (NYSE:ELV) Stock: Insider Mark Kaye Sells 10,584 Shares Elevance Health, Inc. (NYSE: ELV - Get Free Report) CFO Mark Kaye sold 10,584 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
zacks.com ELV vs. RVTY: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang…
benzinga.com TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495 TD Cowen analyst Ryan Langston maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $465 to $495.
benzinga.com UBS Maintains Buy on Elevance Health, Raises Price Target to $523 UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $523.
benzinga.com Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485 Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.
benzinga.com Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449 Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:ELV) with a Equal-Weight and raises the price target from $404 to $449.- benzinga.com RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455 RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and raises the price target from $424 to $455.
- benzinga.com Barclays Maintains Overweight on Elevance Health, Raises Price Target to $472 Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $469 to $472.
benzinga.com Baird Maintains Neutral on Elevance Health, Raises Price Target to $406 Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $393 to $406.
seekingalpha.com Elevance Health: Better Results, But Not Enough To Buy Elevance Health raised its 2026 adjusted EPS guidance to at least $29, but the sustainability of its earnings recovery remains uncertain. Third-quarter adjusted EPS rose 15.9%, while nine-month…
fool.com Elevance: 3 Key Takeaways for Long-Term Investors Elevance raised its 2026 earnings baseline to at least $26.75 per share. Carelon's cancer program reduced avoidable inpatient admissions by 15%.
zacks.com 2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG Intuitive Surgical (ISRG) and Elevance Health (ELV) delivered impressive Q3 earnings beats, making both healthcare stocks worth considering as their growth outlooks improve.
zacks.com Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run? Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
seekingalpha.com Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript
zacks.com ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook Elevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
marketbeat.com What Elevance Health (ELV) Said on Its Q3 Earnings Call Elevance Health NYSE: ELV raised its 2026 earnings outlook after reporting third-quarter adjusted diluted earnings per share of $6.99, exceeding the company's expectations as Medicaid, Medicare…
benzinga.com Meta, Tesla On Deck Wednesday As AI Spending, Auto Demand Face Test Meta Platforms and Tesla headline Wednesday’s reports, with investors focused on whether AI investment can keep driving growth while Tesla’s core auto business weakens. Philip Morris International,…
zacks.com Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key…
benzinga.com Elevance Health Q3 2026 Earnings Call Transcript Elevance Health (NYSE:ELV) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
zacks.com Elevance Health (ELV) Surpasses Q3 Earnings and Revenue Estimates Elevance Health (ELV) came out with quarterly earnings of $6.99 per share, beating the Zacks Consensus Estimate of $4.66 per share. This compares to earnings of $6.03 per share a year ago.
businesswire.com Elevance Health Names Jeff Park President of Carelon INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced the appointment of Jeff Park as President of Carelon, effective December 1, 2026. In this role, Park will lead Carelon…
wsj.com Elevance Health Raises Yearly Outlook as Profit, Revenue Rise For the third quarter, the health-insurance company reported a rise in net income to $1.34 billion, or $6.27 a share, compared with $1.19 billion, or $5.32 a share, a year earlier.
reuters.com Elevance lifts 2026 profit forecast on better medical cost management Elevance lifts 2026 profit forecast on better medical cost management
benzinga.com Elevance Health Q3 Adj. EPS $6.99 Beats $4.68 Estimate, Sales $50.440B Beat $49.213B Estimate Elevance Health (NYSE:ELV) reported quarterly earnings of $6.99 per share which beat the analyst consensus estimate of $4.68 by 49.36 percent. This is a 15.92 percent increase over earnings of $6.03…- benzinga.com Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $460 Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $455 to $460.
- benzinga.com Humana Reaffirms FY26 Adjusted EPS Guidance Of At Least $9; Exceeding Goal Of Top Quartile Results In 2027 Medicare Advantage Star Ratings; Expects 2028 Benefit For One-Time Investments And Return To Shareholders Humana affirms its guidance of at least $9.00 in adjusted earnings per common share ("Adjusted EPS"), for the year ending December 31, 2026 ("FY 2026"). This guidance is consistent with the guidance
benzinga.com Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469 Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $457 to $469.
benzinga.com Stock Market Today: Nasdaq 100 Tumbles as Oil Spikes 6%, Yields Hit 19-Year High Crude jumped 6% and 30-year Treasury yields hit levels last seen in 2007 as a hot PPI print pushed Fed rate-hike odds toward 70% ahead of Friday's CPI.
benzinga.com Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation Elevance Health shares are jumping Thursday after the company reaffirmed its FY26 earnings guidance ahead of a series of investor meetings.
benzinga.com Oil Surges, Treasury Yields Climb a Fifth Day, Software Retreats: Stock Market Today The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Warren Buffett Disciple Seth Klarman Bets on Cruise Lines, Auto Parts, Amazon and Bill Ackman in Q2 Value investor Seth Klarman reveals his latest stock picks in a second quarter filing for hedge fund Baupost Group.
benzinga.com Mark Cuban Wants Investors Out of Health Insurers. That’s Tough If You Own These ETFs Mark Cuban is urging funds to divest from major health insurers. Here’s how broad-market ETFs remain exposed to the companies he’s targeting.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Mark Cuban Urges Investors to Pressure Health Insurers Over Healthcare Costs: ‘You Can Make a Difference’ Mark Cuban urged investors to pressure health insurers over healthcare costs, calling for funds to divest their stakes.- benzinga.com Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395 Leerink Partners analyst Whit Mayo maintains Elevance Health (NYSE:ELV) with a Market Perform and raises the price target from $364 to $395.
benzinga.com UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.
benzinga.com RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424 RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and lowers the price target from $439 to $424.- benzinga.com Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473 Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.
benzinga.com Medicaid's New Twice-A-Year Eligibility Check Starts In December: How To Keep Your Coverage And Which Stocks Feel It Starting in December 2026, millions of Medicaid enrollees will have to prove they still qualify twice as often as they do today, and the Urban Institute estimates the change could push 2 to 3.1…
benzinga.com These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.
benzinga.com Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455 Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.